SCHEMBL13807708

SCHEMBL13807708

CCOC(=O)Cc1nc(CC(=O)N2CCC(c3nc(-c4cc(SC(F)(F)F)cc(C(C)(C)C)c4)c(Cl)s3)CC2)sc1C

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319395 0.92 MAPT (0.31) TP53POLBMAPT
SCHEMBL13807712 0.90 RORC (0.31) TP53POLBMAPT
SCHEMBL13807706 0.89 TP53 (0.32) TP53POLBMAPT
SCHEMBL13807709 0.88 GAA (0.33) TP53POLBMAPT
SCHEMBL13807668 0.83 TP53 (0.33) TP53POLBMAPT
SCHEMBL4311551 0.80 MAPT (0.33) TP53POLBMAPT
SCHEMBL13807178 0.79 KDM4E (0.37) MAPT
SCHEMBL13807722 0.79 TP53 (0.32) TP53POLBMAPT
SCHEMBL13807694 0.78 CCR1 (0.33) TP53POLBMAPT
SCHEMBL4311093 0.77 CCR1 (0.31) TP53POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143413-A1 Thiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-06-04 US disclosed
US-20090143413-A1 Thiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-06-04 US disclosed
WO-2007064553-A2 THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143413-A1 Thiazole Derivatives as CXCR3 Receptor Modulators CXCR3, CXCR1, CX3CR1 TP53 2065/4885POLB 4297/4885MAPT 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.